Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 2
News
News | 01 February 2025

Allergan Aesthetics launches new AA signature program at IMCAS 2025 to redefine patient-centric, multimodal treatment plans

AA Signature provides an innovative approach to treatment planning that focuses on patient outcomes

News
News | 01 February 2025

BMS receives positive CHMP opinion for Opdivo plus Yervoy as a first-line treatment option for advanced hepatocellular carcinoma

Recommendation based on results of Phase 3 CheckMate -9DW clinical trial demonstrating statistically significant and clinically meaningful improvement in overall survival with Opdivo plus Yervoy compared to investigator’s choice of lenvatinib or sorafenib in this patient population

News
News | 01 February 2025

MicrobioTx introduces innovative probiotic range for personalized wellness

These solutions combine scientifically or clinically validated, regulatory-approved probiotic strains with precise dosing

News
News | 31 January 2025

Jubilant Ingrevia commissions new cGMP facility for supplying Niacinamide to global clients

The new facility, which has a capacity of 5,000 metric tonnes, will manufacture nutraceuticals and dietary-active ingredients for human consumption.

News
News | 31 January 2025

Strides reports 14.6% growth in Q3 FY25 revenue

EBITDA grew 46.9% YoY to Rs. 210.3 crore with EBITDA margin at 18.2%, grew 401 bps YoY and the reported PAT at Rs. 90 crore

News
News | 31 January 2025

Biocon posts Q3 FY25 PAT at Rs. 25 Cr

The group reported Q3FY25 operating revenue of Rs 3,821 crore, driven by sustained double-digit growth of 14 per cent in biosimilars

News
News | 30 January 2025

Piramal Pharma Q3 FY25 revenue up 13%

CDMO business delivered high-teen revenue growth for 9MFY25 driven by continued traction in the on-patent commercial manufacturing and generic API business

News
News | 30 January 2025

Enhertu approved in US for breast cancer post more endocrine therapies

Based on DESTINY-Breast06 Phase III trial results which showed Enhertu demonstrated superiority vs. chemotherapy with a median progression-free survival of more than one year

News
News | 29 January 2025

Zota Health Care expands Davaindia Network to 1,413 operational stores

The company remains focused on strengthening its direct retail presence and expanding its reach to more customers across India.

News
News | 29 January 2025

Syensqo partners with MezLight to launch the world’s first sterile reusable surgical task light

Novel illumination system with key components molded in Radel® PPSU for durability and repeated sterilization

News
News | 28 January 2025

Supriya Lifescience posts Q3 FY25 PAT up at Rs. 46.78 Cr

The 33% year-over-year revenue growth and a remarkable 45% surge in gross profit reflect our strong market presence and efficient execution across therapeutic segments

News
News | 28 January 2025

Torrent Pharmaceuticals posts Q3 FY25 consolidated PAT at Rs. 503 Cr

Torrent Pharmaceuticals has reported total income of Rs. 2,842 crores during the period ended December 31, 2024

News
News | 28 January 2025

RPG Life Sciences posts Q3 FY25 PAT higher at Rs. 34.93 Cr

RPG Life Sciences has reported total income of Rs. 176.02 crore during the period ended December 31, 2024

News
News | 28 January 2025

Laurus Labs posts Q3 FY25 consolidated PAT higher at Rs. 92.30 Cr

Laurus Labs has reported total income of Rs. 1,424.47 crores during the period ended December 31, 2024

News
News | 28 January 2025

Toray develops membrane doubling filtration for biopharmaceutical manufacturing processes

The company will initially supply prototypes to diverse customers to evaluate in purification processes for producing gene therapy drugs with a view to swift commercialization

News
News | 27 January 2025

Granules India Q3 FY25 PAT drops 6% to Rs 118 Cr

The company said it voluntarily paused production at the Gagillapur plant in September 2024 for risk assessment on account of the USFDA observations

News
News | 27 January 2025

Pfizer’s BRAFTOVI combination demonstrates improved response for mutant metastatic colorectal cancer

BRAFTOVI combination regimen is the first and only targeted therapy approvedby the U.S. FDA for treatment-naïve patients with metastatic colorectal cancer with a BRAF V600E mutation

News
News | 27 January 2025

SaponiQx, Probius, and Ginkgo Bioworks to revolutionize vaccine adjuvant development

Groundbreaking collaboration harnesses AI-driven insights and advanced manufacturing to create next-generation adjuvants for emerging biological threats

News
News | 27 January 2025

AstraZeneca plans US$ 570 million investment in Canada

700 new scientific and high-skilled jobs to be created in Greater Toronto Area, investing to execute more than 210 AstraZeneca global clinical studies

News
News | 25 January 2025

Cupid gets female condom variant UNFPA prequalified to supply 100% of upcoming South Africa tender

Earlier, Cupid Limited had been eligible to supply 75% of the contract for female condoms in previous tenders

Startup

Digitization